Literature DB >> 17537995

NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.

Annamaria Galietta1, Rosalind H Gunby, Sara Redaelli, Paola Stano, Cristiana Carniti, Angela Bachi, Philip W Tucker, Carmen J Tartari, Ching-Jung Huang, Emanuela Colombo, Karen Pulford, Miriam Puttini, Rocco G Piazza, Holger Ruchatz, Antonello Villa, Arianna Donella-Deana, Oriano Marin, Danilo Perrotti, Carlo Gambacorti-Passerini.   

Abstract

The oncogenic fusion tyrosine kinase nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) induces cellular transformation in anaplastic large-cell lymphomas (ALCLs) carrying the t(2;5) chromosomal translocation. Protein-protein interactions involving NPM/ALK are important for the activation of downstream signaling pathways. This study was aimed at identifying novel NPM/ALK-binding proteins that might contribute to its oncogenic transformation. Using a proteomic approach, several RNA/DNA-binding proteins were found to coimmunoprecipitate with NPM/ALK, including the multifunctional polypyrimidine tract binding proteinassociated splicing factor (PSF). The interaction between NPM/ALK and PSF was dependent on an active ALK kinase domain and PSF was found to be tyrosine-phosphorylated in NPM/ALK-expressing cell lines and in primary ALK(+) ALCL samples. Furthermore, PSF was shown to be a direct substrate of purified ALK kinase domain in vitro, and PSF Tyr293 was identified as the site of phosphorylation. Y293F PSF was not phosphorylated by NPM/ALK and was not delocalized in NPM/ALK(+) cells. The expression of ALK fusion proteins induced delocalization of PSF from the nucleus to the cytoplasm and forced overexpression of PSF-inhibited proliferation and induced apoptosis in cells expressing NPM/ALK. PSF phosphorylation also increased its binding to RNA and decreased the PSF-mediated suppression of GAGE6 expression. These results identify PSF as a novel NPM/ALK-binding protein and substrate, and suggest that PSF function may be perturbed in NPM/ALK-transformed cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17537995      PMCID: PMC1988934          DOI: 10.1182/blood-2006-01-028647

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  83 in total

1.  The prooncoprotein EWS binds calmodulin and is phosphorylated by protein kinase C through an IQ domain.

Authors:  J C Deloulme; L Prichard; O Delattre; D R Storm
Journal:  J Biol Chem       Date:  1997-10-24       Impact factor: 5.157

2.  The RNA-splicing factor PSF/p54 controls DNA-topoisomerase I activity by a direct interaction.

Authors:  T Straub; P Grue; A Uhse; M Lisby; B R Knudsen; T O Tange; O Westergaard; F Boege
Journal:  J Biol Chem       Date:  1998-10-09       Impact factor: 5.157

3.  Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice.

Authors:  M U Kuefer; A T Look; K Pulford; F G Behm; P K Pattengale; D Y Mason; S W Morris
Journal:  Blood       Date:  1997-10-15       Impact factor: 22.113

4.  Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma.

Authors:  J Clark; Y J Lu; S K Sidhar; C Parker; S Gill; D Smedley; R Hamoudi; W M Linehan; J Shipley; C S Cooper
Journal:  Oncogene       Date:  1997-10       Impact factor: 9.867

5.  The KH domain of the branchpoint sequence binding protein determines specificity for the pre-mRNA branchpoint sequence.

Authors:  J A Berglund; M L Fleming; M Rosbash
Journal:  RNA       Date:  1998-08       Impact factor: 4.942

6.  TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis.

Authors:  D Perrotti; S Bonatti; R Trotta; R Martinez; T Skorski; P Salomoni; E Grassilli; R V Lozzo; D R Cooper; B Calabretta
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

7.  In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.

Authors:  P le Coutre; L Mologni; L Cleris; E Marchesi; E Buchdunger; R Giardini; F Formelli; C Gambacorti-Passerini
Journal:  J Natl Cancer Inst       Date:  1999-01-20       Impact factor: 13.506

8.  Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity.

Authors:  R Y Bai; P Dieter; C Peschel; S W Morris; J Duyster
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

Review 9.  Structure and functions of nucleolin.

Authors:  H Ginisty; H Sicard; B Roger; P Bouvet
Journal:  J Cell Sci       Date:  1999-03       Impact factor: 5.285

10.  The nucleolar phosphoprotein B23 redistributes in part to the spindle poles during mitosis.

Authors:  O V Zatsepina; A Rousselet; P K Chan; M O Olson; E G Jordan; M Bornens
Journal:  J Cell Sci       Date:  1999-02       Impact factor: 5.285

View more
  13 in total

1.  Consensus PP1 binding motifs regulate transcriptional corepression and alternative RNA splicing activities of the steroid receptor coregulators, p54nrb and PSF.

Authors:  Liangliang Liu; Ning Xie; Paul Rennie; John R G Challis; Martin Gleave; Stephen J Lye; Xuesen Dong
Journal:  Mol Endocrinol       Date:  2011-05-12

2.  Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.

Authors:  Fang Wu; Peng Wang; Jingdong Zhang; Leah C Young; Raymond Lai; Liang Li
Journal:  Mol Cell Proteomics       Date:  2010-04-14       Impact factor: 5.911

3.  Crystal structure of a SFPQ/PSPC1 heterodimer provides insights into preferential heterodimerization of human DBHS family proteins.

Authors:  Jie Huang; G Patricia Casas Garcia; Matthew A Perugini; Archa H Fox; Charles S Bond; Mihwa Lee
Journal:  J Biol Chem       Date:  2018-03-12       Impact factor: 5.157

4.  The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

Authors:  Raymond Lai; Robert J Ingham
Journal:  Ther Adv Hematol       Date:  2013-04

Review 5.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

Review 6.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

7.  Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.

Authors:  Rocco Piazza; Vera Magistroni; Angela Mogavero; Federica Andreoni; Chiara Ambrogio; Roberto Chiarle; Luca Mologni; Petra S Bachmann; Richard B Lock; Paola Collini; Giuseppe Pelosi; Carlo Gambacorti-Passerini
Journal:  Neoplasia       Date:  2013-05       Impact factor: 5.715

Review 8.  PSF: nuclear busy-body or nuclear facilitator?

Authors:  Christopher A Yarosh; Joseph R Iacona; Carol S Lutz; Kristen W Lynch
Journal:  Wiley Interdiscip Rev RNA       Date:  2015-04-01       Impact factor: 9.957

9.  The DBHS proteins SFPQ, NONO and PSPC1: a multipurpose molecular scaffold.

Authors:  Gavin J Knott; Charles S Bond; Archa H Fox
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

Review 10.  Hacking RNA: Hakai promotes tumorigenesis by enhancing the RNA-binding function of PSF.

Authors:  Angélica Figueroa; Yasuyuki Fujita; Myriam Gorospe
Journal:  Cell Cycle       Date:  2009-11-24       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.